Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDL1-CD47 dual nanobodies
- Development stage
- Preclinical
- Lead developer
- Shaperon
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intraperitoneal, Intravenous
01
Overview
PDL1-CD47 dual nanobodies are a novel class of nanobody-based drugs designed to target both Programmed death-ligand 1 (PDL1) and Cluster of differentiation 47 (CD47) simultaneously. This dual targeting approach aims to enhance anti-tumor immunity by blocking both adaptive and innate immune checkpoints. Developed through a collaboration between Shaperon and Dong-A ST, these nanobodies are being advanced for the treatment of cancer. Shaperon contributes its nanobody development platform, while Dong-A ST provides expertise in antibody commercialization and global biopharmaceutical development. Preclinical results for anti-cancer PDL1-CD47 dual nanobodies have been presented, indicating their technological capabilities.
02
Targets
CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PDL1-CD47 dual nanobodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDL1-CD47 dual nanobodies.